Acknowledgements
S., Sarcomas, Cancer
WRIGHT, SARCOMAS, CANCER
The authors also thank the donors and all the hospitals for participating in patient screening/pre-screening. The authors would like to thank the Spanish Group for Research on Sarcomas (GEIS) for supporting the study Pfizer for providing drug supply and funding for patient screening, and the International Accelerator Award funded by Cancer Research UK [C56167/A29363], Associazione Italiana per la Ricerca sul Cancro [AIRC-24297] and Fundacion Científica—Asociacion Espanola Contra el Cancer [Foundation AECC-GEACC19007MA] for funding translational research. The authors would like to thank Patricio Ledesma, Araceli Rodriguez Morales, and Gabriela Golab for Data Management, Helen Wright for the English edition, and Paloma Sanchez-Bustos and Angela Gavilan for helping with patient screening. David S. Moura is a recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank the SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806. The authors would like to give special thanks to all the patients who participated in the study and their relatives.